CN111983054A - Method for separating and measuring related substances of empagliflozin intermediate by using HPLC (high performance liquid chromatography) - Google Patents
Method for separating and measuring related substances of empagliflozin intermediate by using HPLC (high performance liquid chromatography) Download PDFInfo
- Publication number
- CN111983054A CN111983054A CN202010737639.3A CN202010737639A CN111983054A CN 111983054 A CN111983054 A CN 111983054A CN 202010737639 A CN202010737639 A CN 202010737639A CN 111983054 A CN111983054 A CN 111983054A
- Authority
- CN
- China
- Prior art keywords
- related substances
- separating
- impurity
- empagliflozin
- mobile phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/36—Control of physical parameters of the fluid carrier in high pressure liquid systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/60—Construction of the column
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
- G01N30/8679—Target compound analysis, i.e. whereby a limited number of peaks is analysed
Abstract
The invention provides a method for separating and measuring related substances of an empagliflozin intermediate by using HPLC (high performance liquid chromatography), which comprises the following steps of: octadecylsilane chemically bonded silica is used as a filling agent, water is used as a mobile phase A, acetonitrile-methanol (volume ratio is 60: 40-40: 60) is used as a mobile phase B, gradient elution is carried out, the flow rate is 0.8-1.2 ml/min, the column temperature is 25-40 ℃, the detection wavelength is 205-230 nm, and an ultraviolet detector is adopted to detect related substances of the eprazinone intermediate. The method comprehensively considers the analysis column, the mobile phase, the gradient elution program, the flow rate and the comprehensive influence of the column temperature on the separation detection, optimizes the detection result, has the advantages of rapidness, simplicity, convenience, high sensitivity, accuracy, reliability and wide applicability, and is suitable for separating and determining related substances of the empagliflozin intermediate, thereby effectively controlling the quality of the medicine.
Description
Technical Field
The invention relates to the technical field of analytical chemistry, in particular to a method for separating and determining related substances of an empagliflozin intermediate by using HPLC.
Background
Empagliflozin (Empagliflozin, trade name Jardiance), a novel antidiabetic drug developed by the company brigreville and li, approved by the united states Food and Drug Administration (FDA) for marketing on day 01, 08/2014 for improving glycemic control in type 2 diabetic adult patients. Empagliflozin is a novel sodium-glucose cotransporter 2(SGLT2) inhibitor drug that increases glucose excretion by inhibiting renal reabsorption of glucose, thereby lowering elevated blood glucose levels in diabetic patients.
(1S) -1, 5-anhydro-1-C- [ 4-chloro-3- [ [4- [ [ (3S) -tetrahydro-3-furanyl)]Oxy radical]Phenyl radical]Methyl radical]Phenyl radical]-D-sorbitol tetraacetate is an empagliflozin intermediate of formula: c31H35ClO11Molecular weight: 619.06, the chemical formula is shown as the following formula (1):
in the preparation process of the intermediate, a plurality of impurities are generated due to various factors such as starting materials, synthesis process, degradation and the like, wherein the impurities I, II, III, IV, V, VI and VII are easy to generate in the synthesis process and are used as main inspected impurities in related substance projects, and the limit requirements of the impurities are all less than 0.50 wt%.
Impurity I is a byproduct, and the molecular formula is as follows: c31H35ClO11Molecular weight: 619.06, the chemical formula is shown as the following formula (2):
impurity II is a reaction intermediate in the step 2, and the molecular formula is as follows: c32H37ClO12Molecular weight: 649.08, the chemical formula is shown as the following formula (3):
impurity III is a byproduct, and the molecular formula is as follows: c23H27ClO7Molecular weight: 450.91, the chemical formula is represented by the following formula (4):
the impurity IV is a reaction intermediate in the step 1, and has a molecular formula: c24H29ClO8Molecular weight: 480.94, the chemical formula is shown as the following formula (5):
impurity v is the starting material, molecular formula: c17H16BrClO2Molecular weight: 367.66, the chemical formula is shown as the following formula (6):
impurity VI is a byproduct, and the molecular formula is as follows: c34H32Cl2O4Molecular weight: 575.52, the chemical formula is represented by the following formula (7):
the impurity VII is chiral impurity of empagliflozin intermediate, is coincided with a main peak in reverse phase chromatography and cannot be separated, and needs a normal phase chromatography (chiral) method for control, and has a molecular formula: c31H35ClO11The chemical structural formula is shown as the following formula (8).
The analysis and detection of the intermediate plays an important role in reaction control and yield improvement, and simultaneously directly influences the quality of a final product, so that the establishment of a stable and effective analysis and detection method with simple operation is very necessary for the analysis and detection of the empagliflozin intermediate. In the prior art, no analysis method suitable for quickly, simply and accurately analyzing and detecting related substances of an empagliflozin intermediate exists. Therefore, further improvement and optimization needs exist for the determination method of related substances of the empagliflozin intermediate.
Disclosure of Invention
In order to overcome the technical problems in the prior art, the inventor provides a method for separating and determining related substances of an empagliflozin intermediate by using HPLC (high performance liquid chromatography) after a great deal of intensive research, and the method has the advantages of rapidness, simplicity, high sensitivity, accuracy and reliability.
The technical scheme adopted by the invention is as follows:
a method for separating and measuring related substances of an empagliflozin intermediate by using HPLC (high performance liquid chromatography), comprises the following steps: performing gradient elution by using octadecylsilane chemically bonded silica as a filling agent, using water as a mobile phase A and acetonitrile-methanol as a mobile phase B, wherein the flow rate is 0.8-1.2 ml/min, the column temperature is 25-40 ℃, and the volume ratio of acetonitrile-methanol of the mobile phase B is 60: 40-40: 60; and detecting related substances of the empagliflozin intermediate by adopting an ultraviolet detector, wherein the detection wavelength of the ultraviolet detector is 205-230 nm.
The invention relates to a method for separating and determining related substances of an empagliflozin intermediate by using HPLC, wherein the conditions of gradient elution are as follows:
| time in minutes | Mobile phase A, volume% | Mobile phase B, volume% |
| 0 | 35～45 | 55～65 |
| 35 | 5～15 | 85～95 |
| 50 | 5～15 | 85～95 |
| 51 | 35～45 | 55～65 |
| 65 | 35～45 | 55～65 |
Therefore, the separation degree among the main peak, the impurity I, the impurity II and the impurity III can be improved; if the conditions are changed, the separation degree among the main peak, the impurity I, the impurity II and the impurity III is reduced.
The invention relates to a method for separating and determining related substances of an empagliflozin intermediate by using HPLC, wherein the conditions of gradient elution are as follows:
| time in minutes | Mobile phase A, volume% | Mobile phase B, volume% |
| 0 | 40 | 60 |
| 35 | 10 | 90 |
| 50 | 10 | 90 |
| 51 | 40 | 60 |
| 65 | 40 | 60 |
。
The separation obtained is the best and the peak shape is the best.
The invention relates to a method for separating and measuring related substances of an empagliflozin intermediate by using HPLC, wherein the volume ratio of acetonitrile-methanol in a mobile phase B is 50: 50. Thus, the degree of separation and the number of theoretical plates are both good.
The invention relates to a method for separating and measuring related substances of an empagliflozin intermediate by using HPLC (high performance liquid chromatography), wherein the length of a chromatographic column is 150-250 mm, and the particle size of a filling agent is 1.8-5 mu m.
The invention relates to a method for separating and measuring related substances of an empagliflozin intermediate by using HPLC, wherein the detection wavelength of an ultraviolet detector is 224 nm.
The invention relates to a method for separating and measuring related substances of an eprazimine intermediate by using HPLC (high performance liquid chromatography), wherein the related substances of the eprazimine intermediate comprise one or more of an impurity I, an impurity II, an impurity III, an impurity IV, an impurity V and an impurity VI, and the specific structural formula is as follows:
the invention relates to a method for separating and measuring related substances of an empagliflozin intermediate by using HPLC, wherein the length of a chromatographic column is 250 mm. Therefore, the separation degree among the main peak, the impurity I, the impurity II and the impurity III can be further improved.
The invention relates to a method for separating and measuring empagliflozin intermediate related substances by using HPLC, wherein the particle size of a filling agent is 5 mu m. This can further improve the degree of separation.
The method for separating and measuring related substances of the empagliflozin intermediate by using HPLC (high performance liquid chromatography) is characterized in that the flow rate is 1.0ml/min, and the column temperature is 35 ℃. This can further improve the degree of separation.
Compared with the prior art, the invention has the following beneficial effects:
the method for separating and determining related substances of the eprazim intermediate by using HPLC comprehensively considers the comprehensive influence of an analytical column, a mobile phase, a gradient elution program, flow velocity and column temperature on separation and detection, so that the detection result is optimized, the impurities I, II, III, IV, V and VI in the eprazim intermediate can be quickly and efficiently separated under the same chromatographic condition, and the detection method has the advantages of high sensitivity, strong specificity, strong accuracy, quickness, simplicity and convenience in operation, can effectively control the quality of a medicine, and is suitable for separating and determining related substances of the eprazim intermediate.
Drawings
FIG. 1 is a chromatogram of a blank solution tested under the conditions of example 1 in accordance with the present invention;
FIG. 2 is a chromatogram of a system suitability solution tested under the conditions of example 1 in the present invention;
FIG. 3 is a chromatogram of a test solution tested under the conditions of example 1 in accordance with the present invention;
FIG. 4 is a chromatogram of a limiting quantitation solution detected under the conditions of example 1 in the present invention;
FIG. 5 is a chromatogram of a detection limiting solution detected under the conditions of example 1 in the present invention;
FIG. 6 is a chromatogram of a blank solution tested under the conditions of example 2 in accordance with the present invention;
FIG. 7 is a chromatogram of a system suitability solution tested under the conditions of example 2 in the present invention;
FIG. 8 is a chromatogram of a test solution tested under the conditions of example 2 in accordance with the present invention;
FIG. 9 is a chromatogram of a limiting quantitation solution detected under the conditions of example 2 in the present invention;
FIG. 10 is a chromatogram of a detection limiting solution detected under the conditions of example 2 in the present invention;
FIG. 11 is a chromatogram of a blank solution tested under the conditions of example 3 in accordance with the present invention;
FIG. 12 is a chromatogram of a system suitability solution tested under the conditions of example 3 in the present invention;
FIG. 13 is a chromatogram of a test solution tested under the conditions of example 3 in accordance with the present invention;
FIG. 14 is a chromatogram of a limiting quantitation solution detected under the conditions of example 3 in the present invention;
FIG. 15 is a chromatogram of a detection-limiting solution detected under the conditions of example 3 in the present invention.
Detailed Description
The present invention will be described in detail below with reference to specific embodiments and the accompanying drawings. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that variations and modifications can be made by persons skilled in the art without departing from the spirit of the invention. All falling within the scope of the present invention. The reagents and instruments used are not indicated by manufacturers, and conventional products can be obtained commercially.
The empagliflozin intermediate and the impurity reference substance used in the embodiment of the invention are prepared by the inventor.
Example 1
The chromatographic conditions were as follows:
a chromatographic column: agilent TC-C18250 multiplied by 4.6mm
Mobile phase A: water (W)
Mobile phase B: acetonitrile: methanol (volume ratio 60:40)
Column temperature: 35 deg.C
Flow rate: 1.0ml/min
Detection wavelength: 224nm
Sample introduction amount: 20 μ L
The gradient elution procedure was:
TABLE 1 gradient elution procedure
| Time in minutes | Mobile phase A, volume% | Mobile phase B, |
| 0 | 40 | 60 |
| 35 | 10 | 90 |
| 50 | 10 | 90 |
| 51 | 40 | 60 |
| 65 | 40 | 60 |
Solution preparation:
impurity reference stock solution: precisely weighing about 12.5mg of impurity I reference substance, impurity II reference substance, impurity III reference substance, impurity IV reference substance, impurity V reference substance and impurity VI reference substance, placing in a 25ml measuring flask, adding diluent to dissolve and dilute to scale, and shaking uniformly to obtain the final product; the diluent is as follows: acetonitrile-water (50:50) (V/V).
System applicability solution: precisely weighing about 50mg of empagliflozin intermediate working reference substance, placing into a 100ml measuring flask, precisely adding 1ml of impurity reference substance stock solution into the 100ml measuring flask, adding diluent to dilute to scale, and shaking up to obtain the final product.
Test solution: taking about 50mg of empagliflozin intermediate, precisely weighing, placing in a 100ml measuring flask, adding a diluent to dissolve and dilute to a scale, and shaking up.
Empagliflozin intermediate control stock solution: precisely weighing about 50mg of the epraziquant intermediate working reference substance, placing the weighed product into a 100ml measuring flask, adding a diluent to dissolve and dilute the product to a scale, and shaking up the product to obtain the epraziquant intermediate.
Quantitative limiting solution: precisely measuring the impurity reference substance storage solution and the eprazimutm intermediate reference substance storage solution in measuring bottles of 1ml to 100ml respectively, adding a diluent to dilute to a scale, shaking up, precisely measuring 1ml to 25ml, adding the diluent to dilute to the scale, and shaking up to obtain the empagliflozin intermediate reference substance.
Detection limiting solution: precisely measuring 5ml of the quantitative limiting solution, putting the quantitative limiting solution into a 10ml measuring flask, adding a diluent to dilute to a scale, and shaking up to obtain the product.
And (3) determination: respectively injecting blank solution (namely diluent), system applicability solution, sample solution, quantitative limiting solution and detection limiting solution into a high performance liquid chromatograph for detection, using octadecylsilane chemically bonded silica as a filler (the particle size is 5 mu m, the inner diameter of a column is 4.6mm, the length of a chromatographic column is 250mm), detecting according to a gradient elution program in Table 1, and recording a chromatogram.
Chromatograms of the blank solution (i.e., diluent), the system applicability solution, the sample solution, the quantification limit solution, and the detection limit solution are shown in fig. 1, 2, 3, 4, and 5, respectively, and it can be seen that fig. 1 shows that the blank does not interfere with the inspection of impurities; FIG. 2 shows that the separation degree between each impurity and an empagliflozin intermediate is good, and the specific applicability map data of the empagliflozin intermediate system is shown in Table 2, wherein the impurity III is a pair of non-corresponding isomer impurities and shows a double peak in reverse chromatogram, so 21.556min and 22.263min are retention time of the impurity III; FIG. 3 shows that impurities III, IV, V and VI are not detected in a self-made eprazimutm intermediate sample, and the detected impurities I and II are both below 0.5 wt%; the other single impurities detected are all below 0.5 wt%; FIG. 4 shows that the quantitative limits of empagliflozin intermediate and impurity I, impurity II, impurity III, impurity IV, impurity V, and impurity VI are 0.04 wt%, and 0.04 wt%, respectively; FIG. 5 shows that the detection limits of empagliflozin intermediate and impurity I, impurity II, impurity III, impurity IV, impurity V and impurity VI are 0.02 wt%, and 0.02 wt%, respectively, which are lower than the limit of each impurity by 0.50 wt%; the method has high detection sensitivity.
TABLE 2 data Table of empagliflozin system applicability profiles in example 1
Example 2
The chromatographic conditions were as follows:
a chromatographic column: agilent TC-C18250 multiplied by 4.6mm
Mobile phase A: water (W)
Mobile phase B: acetonitrile: methanol (volume ratio 40:60)
Column temperature: 35 deg.C
Flow rate: 1.0ml/min
Detection wavelength: 224nm
Sample introduction amount: 20 μ l
The gradient elution procedure was:
TABLE 3 gradient elution procedure
| Time in minutes | Mobile phase A, volume% | Mobile phase B, |
| 0 | 40 | 60 |
| 35 | 10 | 90 |
| 50 | 10 | 90 |
| 51 | 40 | 60 |
| 65 | 40 | 60 |
Solution preparation:
impurity reference stock solution: precisely weighing about 12.5mg of impurity I reference substance, impurity II reference substance, impurity III reference substance, impurity IV reference substance, impurity V reference substance and impurity VI reference substance, placing in a 25ml measuring flask, adding diluent to dissolve and dilute to scale, and shaking uniformly to obtain the final product; the diluent is as follows: acetonitrile-water (50:50) (V/V).
System applicability solution: precisely weighing about 50mg of empagliflozin intermediate working reference substance, placing into a 100ml measuring flask, precisely adding 1ml of impurity reference substance stock solution into the 100ml measuring flask, adding diluent to dilute to scale, and shaking up to obtain the final product.
Test solution: taking about 50mg of empagliflozin intermediate, precisely weighing, placing in a 100ml measuring flask, adding a diluent to dissolve and dilute to a scale, and shaking up.
Empagliflozin intermediate control stock solution: precisely weighing about 50mg of the epraziquant intermediate working reference substance, placing the weighed product into a 100ml measuring flask, adding a diluent to dissolve and dilute the product to a scale, and shaking up the product to obtain the epraziquant intermediate.
Quantitative limiting solution: precisely measuring the impurity reference substance storage solution and the eprazimutm intermediate reference substance storage solution in measuring bottles of 1ml to 100ml respectively, adding a diluent to dilute to a scale, shaking up, precisely measuring 1ml to 25ml, adding the diluent to dilute to the scale, and shaking up to obtain the empagliflozin intermediate reference substance.
Detection limiting solution: precisely measuring 5ml of the quantitative limiting solution, putting the quantitative limiting solution into a 10ml measuring flask, adding a diluent to dilute to a scale, and shaking up to obtain the product.
And (3) determination: respectively injecting blank solution (namely diluent), system applicability solution, sample solution, quantitative limiting solution and detection limiting solution into a high performance liquid chromatograph for detection, using octadecylsilane chemically bonded silica as a filler (the particle size is 5 mu m, the inner diameter of a column is 4.6mm, the length of a chromatographic column is 250mm), detecting according to a gradient elution program shown in Table 3, and recording a chromatogram.
Chromatograms of the blank solution (i.e., diluent), the system applicability solution, the sample solution, the quantification limit solution, and the detection limit solution are shown in fig. 6, 7, 8, 9, and 10, respectively, and it can be seen that fig. 6 shows that the blank does not interfere with the impurity inspection; FIG. 7 shows that the separation degree between each impurity and an empagliflozin intermediate is good, and the system applicability map data of the empagliflozin intermediate is shown in Table 4, wherein the impurity III is a pair of non-corresponding isomer impurities and shows a double peak in reverse phase chromatography, so that 24.965min and 25.920min are retention times of the impurity III; FIG. 8 shows that impurities III, IV, V and VI are not detected in a self-made eprazimutm intermediate sample, and the detected impurities I and II are both below 0.5 wt%; the other single impurities detected are all below 0.5 wt%; FIG. 9 shows that the quantitative limits of empagliflozin intermediate and impurity I, impurity II, impurity III, impurity IV, impurity V, and impurity VI are 0.04 wt%, and 0.04 wt%, respectively; FIG. 10 shows that the detection limits of empagliflozin intermediate and impurity I, impurity II, impurity III, impurity IV, impurity V and impurity VI are 0.02 wt%, and 0.02 wt%, respectively, which are lower than the limit of each impurity by 0.50 wt%; the method has high detection sensitivity.
Table 4 data table of empagliflozin system applicability profiles in example 2
Example 3
The chromatographic conditions were as follows:
a chromatographic column: agilent TC-C18250 multiplied by 4.6mm
Mobile phase A: water (W)
Mobile phase B: acetonitrile: methanol (volume ratio 50:50)
Column temperature: 35 deg.C
Flow rate: 1.0ml/min
Detection wavelength: 224nm
Sample introduction amount: 20 μ l
The gradient elution procedure was:
TABLE 5 gradient elution procedure
| Time in minutes | Mobile phase A, volume% | Mobile phase B, |
| 0 | 40 | 60 |
| 35 | 10 | 90 |
| 50 | 10 | 90 |
| 51 | 40 | 60 |
| 65 | 40 | 60 |
Solution preparation:
impurity reference stock solution: precisely weighing about 12.5mg of impurity I reference substance, impurity II reference substance, impurity III reference substance, impurity IV reference substance, impurity V reference substance and impurity VI reference substance, placing in a 25ml measuring flask, adding diluent to dissolve and dilute to scale, and shaking uniformly to obtain the final product; the diluent is as follows: acetonitrile-water (50:50) (V/V).
System applicability solution: precisely weighing about 50mg of empagliflozin intermediate working reference substance, placing into a 100ml measuring flask, precisely adding 1ml of impurity reference substance stock solution into the 100ml measuring flask, adding diluent to dilute to scale, and shaking up to obtain the final product.
Test solution: taking about 50mg of empagliflozin intermediate, precisely weighing, placing in a 100ml measuring flask, adding a diluent to dissolve and dilute to a scale, and shaking up.
Empagliflozin intermediate control stock solution: precisely weighing about 50mg of the epraziquant intermediate working reference substance, placing the weighed product into a 100ml measuring flask, adding a diluent to dissolve and dilute the product to a scale, and shaking up the product to obtain the epraziquant intermediate.
Quantitative limiting solution: precisely measuring the impurity reference substance storage solution and the eprazimutm intermediate reference substance storage solution in measuring bottles of 1ml to 100ml respectively, adding a diluent to dilute to a scale, shaking up, precisely measuring 1ml to 25ml, adding the diluent to dilute to the scale, and shaking up to obtain the empagliflozin intermediate reference substance.
Detection limiting solution: precisely measuring 5ml of the quantitative limiting solution, putting the quantitative limiting solution into a 10ml measuring flask, adding a diluent to dilute to a scale, and shaking up to obtain the product.
And (3) determination: respectively injecting blank solution (namely diluent), system applicability solution, sample solution, quantitative limiting solution and detection limiting solution into a high performance liquid chromatograph for detection, using octadecylsilane chemically bonded silica as a filler (the particle size is 5 mu m, the inner diameter of a column is 4.6mm, the length of a chromatographic column is 250mm), detecting according to a gradient elution program shown in Table 5, and recording a chromatogram.
Chromatograms of the blank solution (i.e., diluent), the system applicability solution, the sample solution, the quantification limit solution, and the detection limit solution are shown in fig. 11, 12, 13, 14, and 15, respectively, and it can be seen that fig. 11 shows that the blank does not interfere with the impurity inspection; FIG. 12 shows that the separation between each impurity and the epraziquant intermediate is good, and the system applicability map data of the epraziquant intermediate is shown in Table 6, wherein the impurity III is a pair of non-corresponding isomer impurities and shows a double peak in reverse phase chromatography, so that 22.671min and 23.487min are retention times of the impurity III; FIG. 13 shows that impurities III, IV, V and VI are not detected in a self-made eprazimutm intermediate sample, and the detected impurities I and II are both below 0.5 wt%; the other single impurities detected are all below 0.5 wt%; FIG. 14 shows that the quantitation limits of empagliflozin intermediate and impurity I, impurity II, impurity III, impurity IV, impurity V, and impurity VI are 0.04 wt%, and 0.04 wt%, respectively; FIG. 15 shows that the detection limits of empagliflozin intermediate and impurity I, impurity II, impurity III, impurity IV, impurity V, and impurity VI are 0.02 wt%, and 0.02 wt%, respectively, which are lower than the limit of each impurity by 0.50 wt%; the method has high detection sensitivity.
Table 6 data table of empagliflozin system applicability profiles in example 3
The above-mentioned embodiments are merely illustrative of the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various modifications and improvements of the technical solution of the present invention by those skilled in the art should fall within the protection scope defined by the claims of the present invention without departing from the spirit of the present invention.
Claims (10)
1. A method for separating and measuring related substances of an empagliflozin intermediate by using HPLC (high performance liquid chromatography), which is characterized by comprising the following steps: the method comprises the following steps: performing gradient elution by using octadecylsilane chemically bonded silica as a filling agent, using water as a mobile phase A and acetonitrile-methanol as a mobile phase B, wherein the flow rate is 0.8-1.2 ml/min, the column temperature is 25-40 ℃, and the volume ratio of acetonitrile-methanol of the mobile phase B is 60: 40-40: 60; and detecting related substances of the empagliflozin intermediate by adopting an ultraviolet detector, wherein the detection wavelength of the ultraviolet detector is 205-230 nm.
2. The method for separating and determining empagliflozin intermediate related substances by HPLC according to claim 1, wherein: the conditions of the gradient elution are as follows:
。
3. The method for separating and determining empagliflozin intermediate related substances by HPLC according to claim 1, wherein: the conditions of the gradient elution are as follows:
。
4. The method for separating and determining empagliflozin intermediate related substances by HPLC according to claim 1, wherein: mobile phase B acetonitrile-methanol volume ratio was 50: 50.
5. The method for separating and determining empagliflozin intermediate related substances by HPLC according to claim 1, wherein: the length of the chromatographic column is 150 mm-250 mm, and the particle size of the filler is 1.8-5 mu m.
6. The method for separating and determining empagliflozin intermediate related substances by HPLC according to claim 1, wherein: the detection wavelength of the ultraviolet detector is 224 nm.
7. The method for separating and determining empagliflozin intermediate related substances by HPLC according to claim 1, wherein: the related substances of the empagliflozin intermediate comprise one or more of impurities I, II, III, IV, V and VI, and the specific structural formula is as follows:
8. the method for separating and determining empagliflozin intermediate related substances by HPLC according to claim 1, wherein: the column length was 250 mm.
9. The method for separating and determining empagliflozin intermediate related substances by HPLC according to claim 1, wherein: the particle size of the filler is 5 mu m.
10. The method for separating and determining empagliflozin intermediate related substances by HPLC according to any one of claims 1 to 9, wherein: the flow rate was 1.0ml/min and the column temperature was 35 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010737639.3A CN111983054B (en) | 2020-07-28 | 2020-07-28 | Method for separating and measuring related substances of empagliflozin intermediate by using HPLC (high performance liquid chromatography) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010737639.3A CN111983054B (en) | 2020-07-28 | 2020-07-28 | Method for separating and measuring related substances of empagliflozin intermediate by using HPLC (high performance liquid chromatography) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111983054A true CN111983054A (en) | 2020-11-24 |
| CN111983054B CN111983054B (en) | 2022-06-07 |
Family
ID=73444459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010737639.3A Active CN111983054B (en) | 2020-07-28 | 2020-07-28 | Method for separating and measuring related substances of empagliflozin intermediate by using HPLC (high performance liquid chromatography) |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111983054B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114264747A (en) * | 2021-12-27 | 2022-04-01 | 浙江海翔药业股份有限公司 | High performance liquid chromatography detection method for empagliflozin intermediate and related substances thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104788438A (en) * | 2015-05-04 | 2015-07-22 | 南京华威医药科技开发有限公司 | B crystal form of empagliflozin and preparation of B crystal form |
| WO2017027611A2 (en) * | 2015-08-10 | 2017-02-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Biomarkers of methylglyoxal and related methods thereof |
| CN106706768A (en) * | 2015-11-17 | 2017-05-24 | 重庆医药工业研究院有限责任公司 | Method for measuring Jardiance and related substances of Jardiance through separation |
| US20170247356A1 (en) * | 2015-11-09 | 2017-08-31 | Cadila Healthcare Limited | Processes for the preparation of empagliflozin |
| CN109374782A (en) * | 2018-12-21 | 2019-02-22 | 安徽联创生物医药股份有限公司 | A method of with the related substance of the net bulk pharmaceutical chemicals of HPLC separation determination Yi Palie |
| CN110824038A (en) * | 2019-10-28 | 2020-02-21 | 南京圣鼎医药科技有限公司 | Liquid chromatography analysis method of 2,3,4, 6-tetra-O-trimethylsilyl-D-gluconolactone |
-
2020
- 2020-07-28 CN CN202010737639.3A patent/CN111983054B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104788438A (en) * | 2015-05-04 | 2015-07-22 | 南京华威医药科技开发有限公司 | B crystal form of empagliflozin and preparation of B crystal form |
| WO2017027611A2 (en) * | 2015-08-10 | 2017-02-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Biomarkers of methylglyoxal and related methods thereof |
| US20170247356A1 (en) * | 2015-11-09 | 2017-08-31 | Cadila Healthcare Limited | Processes for the preparation of empagliflozin |
| CN106706768A (en) * | 2015-11-17 | 2017-05-24 | 重庆医药工业研究院有限责任公司 | Method for measuring Jardiance and related substances of Jardiance through separation |
| CN109374782A (en) * | 2018-12-21 | 2019-02-22 | 安徽联创生物医药股份有限公司 | A method of with the related substance of the net bulk pharmaceutical chemicals of HPLC separation determination Yi Palie |
| CN110824038A (en) * | 2019-10-28 | 2020-02-21 | 南京圣鼎医药科技有限公司 | Liquid chromatography analysis method of 2,3,4, 6-tetra-O-trimethylsilyl-D-gluconolactone |
Non-Patent Citations (4)
| Title |
|---|
| JOANNA WITTCKIND MANOEL 等: "The application of quality by design in the development of the liquid chromatography method to determine empagliflozin in the presence of its organic impurities", 《RSC ADVANCES》 * |
| SUSHIL H. JAISWAL 等: "VALIDATED STABILITY INDICATING HPLC METHOD FOR DETERMINATION OF PROCESS RELATED IMPURITIES IN EMPAGLIFLOZIN DRUG SUBSTANCES", 《WORLD JOURNAL OF PHARMACEUTICAL RESEARCH》 * |
| 石克金 等: "恩格列净合成工艺改进", 《中国医药工业杂志》 * |
| 郝文静 等: "HPLC 法测定恩格列净片的有关物质", 《药物分析杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114264747A (en) * | 2021-12-27 | 2022-04-01 | 浙江海翔药业股份有限公司 | High performance liquid chromatography detection method for empagliflozin intermediate and related substances thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111983054B (en) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109374784B (en) | Method for separating and measuring related substances of dapagliflozin bulk drug by using HPLC (high performance liquid chromatography) | |
| CN114264747A (en) | High performance liquid chromatography detection method for empagliflozin intermediate and related substances thereof | |
| CN111983055B (en) | Method for separating and measuring rivaroxaban intermediate related substances by using HPLC (high performance liquid chromatography) | |
| CN108982695A (en) | The method that derivatization HPLC method measures azido compound in drug or in which mesosome | |
| CN111983054B (en) | Method for separating and measuring related substances of empagliflozin intermediate by using HPLC (high performance liquid chromatography) | |
| CN109374782B (en) | Method for separating and measuring related substances of empagliflozin bulk drug by using HPLC (high performance liquid chromatography) | |
| CN108061767B (en) | Method for separating and measuring rivaroxaban intermediate and related impurities thereof by HP L C method | |
| CN112014510B (en) | Detection method for determining chloroacetic acid residue in cinepazide maleate intermediate by HPLC (high performance liquid chromatography) method | |
| CN107843656B (en) | Detection method of 2, 4-dimethylthiophenol related substances | |
| CN110514759B (en) | Method for detecting azide in candesartan cilexetil | |
| CN111983056B (en) | Method for separating and measuring related substances of tofacitinib intermediate by using HPLC (high performance liquid chromatography) | |
| CN114184699B (en) | Method for determining potential genotoxic impurities in esomeprazole sodium by liquid chromatography-mass spectrometry | |
| CN114264765B (en) | Analytical method for determining related substances in glimepiride intermediate by utilizing HPLC | |
| CN110412164B (en) | Method for detecting related substances of mexiletine hydrochloride | |
| CN109374783B (en) | Method for separating and determining related substances of canagliflozin bulk drug by using HPLC (high performance liquid chromatography) | |
| CN109738536B (en) | Method for separating benzaldehyde and nitrobenzaldehyde by using high performance liquid chromatography | |
| CN115774061A (en) | Method for detecting acetic acid in 1-cyclohexyl piperazine | |
| CN111999400B (en) | Method for separating and determining impurities of bulk drugs of baricitinib by using HPLC (high performance liquid chromatography) | |
| CN116338021A (en) | Method for separating and measuring related substances of dapagliflozin key starting material by using HPLC | |
| CN114235998B (en) | Method for measuring related substances in carteolol hydrochloride and eye drops thereof by ultra-performance liquid chromatography | |
| CN114577944B (en) | Detection method for related substances in 5-bromo-2-chloro-4' -ethoxydiphenylmethane | |
| CN113406236B (en) | Method for detecting impurities in 1- (3-pyridyl) -3- (dimethylamino) -2-propylene-1-ketone | |
| CN114544850B (en) | Dapagliflozin intermediate and impurity detection method | |
| CN114295750B (en) | Method for detecting related substances in ursodeoxycholic acid synthesis | |
| CN115267021B (en) | Liquid chromatographic analysis method for L-prolyl amide related substances |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |